Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SYNAGEVA BIOPHARMA CORPFinancial_Report.xls
EX-31.2 - SECTION 302 CFO CERTIFICATION - SYNAGEVA BIOPHARMA CORPd329373dex312.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - SYNAGEVA BIOPHARMA CORPd329373dex311.htm
EX-10.1 - BIOPHARMACEUTICAL SERVICES AGREEMENT - SYNAGEVA BIOPHARMA CORPd329373dex101.htm
10-Q - FORM 10-Q - SYNAGEVA BIOPHARMA CORPd329373d10q.htm
EX-10.2 - AMENDMENT TO THE BIOPHARMACEUTICAL SERVICES AGREEMENT - SYNAGEVA BIOPHARMA CORPd329373dex102.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned, as principal executive officer and principal financial officer of Synageva BioPharma Corp. (the “Company”), does hereby certify that to such officer’s knowledge:

(1) the Company’s Form 10-Q for the period ended March 31, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Company’s Form 10-Q for the period ended March 31, 2012 fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Sanj K. Patel

Sanj K. Patel

President and Chief Executive Officer

/s/ Carsten Boess

Carsten Boess

Chief Financial Officer

Date: May 9, 2012

 

* A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Synageva BioPharma Corp. and will be retained by Synageva BioPharma Corp. and provided to the Securities and Exchange Commission or its staff upon request.